Patents by Inventor YONGBAO WANG
YONGBAO WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230193358Abstract: The present invention provides methods and compositions for determining prognosis in individual with cancer, in particular endometrial cancer. The present invention also provides methods of developing and using predictive models that are useful for determining prognosis of endometrial cancer and other similar diseases. The present invention further provides methods for determining microsatellite status using next generation sequencing.Type: ApplicationFiled: February 21, 2023Publication date: June 22, 2023Applicant: Quest Diagnostics Investments LLCInventors: Yongbao WANG, Kevin J. ARVAI, Daniel JONES
-
Publication number: 20220364180Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.Type: ApplicationFiled: February 4, 2022Publication date: November 17, 2022Applicant: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Yongbao Wang, Daniel Jones
-
Patent number: 11118232Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: GrantFiled: December 17, 2018Date of Patent: September 14, 2021Assignee: Quest Diagnostics Investments LLCInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Publication number: 20200165688Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.Type: ApplicationFiled: December 19, 2019Publication date: May 28, 2020Applicant: QUEST DIAGNOSTICS INVESTMENT LLCInventors: Yongbao Wang, Daniel Jones
-
Patent number: 10519509Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.Type: GrantFiled: April 22, 2016Date of Patent: December 31, 2019Assignee: Quest Diagnostics Investments IncorporatedInventors: Yongbao Wang, Daniel Jones
-
Publication number: 20190177801Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: ApplicationFiled: December 17, 2018Publication date: June 13, 2019Applicant: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Patent number: 10155994Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: GrantFiled: March 10, 2017Date of Patent: December 18, 2018Assignee: Quest Diagnostics Investments IncorporatedInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Publication number: 20180094301Abstract: The present invention provides methods and compositions for determining prognosis in individual with cancer, in particular endometrial cancer. The present invention also provides methods of developing and using predictive models that are useful for determining prognosis of endometrial cancer and other similar diseases. The present invention further provides methods for determining microsatellite status using next generation sequencing.Type: ApplicationFiled: February 5, 2016Publication date: April 5, 2018Applicant: Quest Diagnostics Investments LLCInventors: Yongbao WANG, Kevin J. ARVAI, Daniel JONES
-
Publication number: 20170260591Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: ApplicationFiled: March 10, 2017Publication date: September 14, 2017Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Patent number: 9617579Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: GrantFiled: December 26, 2013Date of Patent: April 11, 2017Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Publication number: 20160312303Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.Type: ApplicationFiled: April 22, 2016Publication date: October 27, 2016Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Yongbao Wang, Daniel Jones
-
Publication number: 20140220032Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: ApplicationFiled: December 26, 2013Publication date: August 7, 2014Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: DANIEL M. JONES, YONGBAO WANG, SHERE BILLOUIN-FRAZIER, JUSTIN WINDHAM